Mbx Biosciences (MBX): Longaeva Partners L.P. exited its position 224K shares
Longaeva Partners L.P. exited its position in Mbx Biosciences, per its Q4 2025 13F.
- 224K
- Prior-quarter shares · no longer reported
- Holdings as of
- Dec 31, 2025
- Filed
- Feb 17, 2026
What stands out in this filing
- The manager reported no shares in Q4 2025, after 224,433 in its Q3 2025 filing.
- 2 other tracked managers reported the same kind of change for Q4 2025.
Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Jan 11, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors (and 1 more item)
- Jan 20, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“Effective as of January 20, 2026, the board of directors (the “Board”) of MBX Biosciences, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “NCG Committee”), appointed Laurie Stelzer as a director of the Company.”
What came next
- Feb 24, 2026Company filing · Form 8-K · Material agreement, Executive changeChanged a top executive or board member, and signed an important agreement“On February 25, 2026, the Company and Richard Bartram entered into a separation agreement pursuant to which Mr. Bartram will resign as Chief Financial Officer of the Company.”
- Mar 12, 2026Company filing · Form 8-K · ResultsReported its results
- May 7, 2026Company filing · Form 8-K · ResultsReported its results
- Jun 4, 2026Company filing · Form 8-K · Executive change, Shareholder voteChanged a top executive or board member, and held a shareholder vote“On June 4, 2026, MBX Biosciences, Inc. (the "Company") held its 2026 annual meeting of stockholders (the "Annual Meeting"). As further described under Item 5.07 below, the Company's stockholders approved the election of two Class II directors to serve for a three-year term ending at the annual meeting of stockholders to be held in 2029.”
How to read SEC Form 13F-HR
Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.
Full guide: What is an SEC Form 13F?
What else is on file for Mbx Biosciences
For Mbx Biosciences, OQRO holds 4 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its MBX page.
How this filing works
Explore the data
Common questions
What does this filing report about Mbx Biosciences (MBX) stock?
Longaeva Partners L.P. exited its position in Mbx Biosciences, per its Q4 2025 13F. Held the prior quarter, no longer listed per its Q4 2025 13F.
When did it happen, and when was it made public?
Holdings as of: Dec 31, 2025. Filed: Feb 17, 2026.
What stands out in this filing?
The manager reported no shares in Q4 2025, after 224,433 in its Q3 2025 filing. 2 other tracked managers reported the same kind of change for Q4 2025.
Is this a trade made on a known date?
No. A holdings report is a picture of the portfolio on the last day of the quarter. It shows what was held on that day, not the day or the price at which anything was bought or sold.
Where does this information come from?
From the SEC Form 13F-HR, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Mbx Biosciences recently?
For Mbx Biosciences, OQRO holds 4 insider filings (SEC Form 4 or Form 144) dated in the last 90 days. They are listed on the MBX page.
Does this mean MBX stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Mbx Biosciences
- SEC Form 4Nov 12, 2026
- SEC Form 144Nov 10, 2026
- SEC Form 4Nov 5, 2026
- SEC Form 144Nov 4, 2026
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRAug 14, 2026
Everything OQRO holds on this company is on its MBX page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
